| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| K S Kee, R S Kern, B D Marshall, M F Gree. Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. Schizophrenia research. vol 31. issue 2-3. 1998-11-09. PMID:9689720. |
risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. |
1998-11-09 |
2023-08-12 |
Not clear |
| K S Kee, R S Kern, B D Marshall, M F Gree. Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. Schizophrenia research. vol 31. issue 2-3. 1998-11-09. PMID:9689720. |
the present study was designed to compare the effects of risperidone versus haloperidol on the ability to perceive emotion in 20 treatment-resistant schizophrenia patients, using a double-blind design. |
1998-11-09 |
2023-08-12 |
Not clear |
| S Kasper, B Küfferl. Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and Associates. Journal of clinical psychopharmacology. vol 18. issue 4. 1998-10-28. PMID:9690709. |
comments on "double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by tran and associates. |
1998-10-28 |
2023-08-12 |
Not clear |
| H J Möller, C A Gagiano, D E Addington, L Von Knorring, J F Torres-Plank, C Gaussare. Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. International clinical psychopharmacology. vol 13. issue 3. 1998-10-28. PMID:9690975. |
long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. |
1998-10-28 |
2023-08-12 |
Not clear |
| H J Möller, C A Gagiano, D E Addington, L Von Knorring, J F Torres-Plank, C Gaussare. Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. International clinical psychopharmacology. vol 13. issue 3. 1998-10-28. PMID:9690975. |
an open-label, multicentre study was conducted to assess the long-term efficacy and safety of risperidone in patients with chronic schizophrenia. |
1998-10-28 |
2023-08-12 |
Not clear |
| H J Möller, C A Gagiano, D E Addington, L Von Knorring, J F Torres-Plank, C Gaussare. Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. International clinical psychopharmacology. vol 13. issue 3. 1998-10-28. PMID:9690975. |
the results demonstrate that risperidone's efficacy against the positive and negative symptoms of chronic schizophrenia can be maintained in long-term treatment with a low incidence of adverse experiences; moreover, the drug reduces preexisting extrapyramidal symptoms over time. |
1998-10-28 |
2023-08-12 |
Not clear |
| R S Shiwach, T J Carmod. Prolactogenic effects of risperidone in male patients--a preliminary study. Acta psychiatrica Scandinavica. vol 98. issue 1. 1998-10-28. PMID:9696519. |
this preliminary study describes a case of a male patient who developed gynaecomastia and sexual difficulties whilst taking risperidone for chronic paranoid schizophrenia. |
1998-10-28 |
2023-08-12 |
Not clear |
| S A Cohen, K Ihrig, R S Lott, J M Kerric. Risperidone for aggression and self-injurious behavior in adults with mental retardation. Journal of autism and developmental disorders. vol 28. issue 3. 1998-10-08. PMID:9656134. |
risperidone has proven efficacy with reduced likelihood of causing extrapyramidal symptoms in the treatment of schizophrenia. |
1998-10-08 |
2023-08-12 |
Not clear |
| R H Foster, K L Go. Risperidone. A pharmacoeconomic review of its use in schizophrenia. PharmacoEconomics. vol 14. issue 1. 1998-09-22. PMID:10182198. |
the use of risperidone in preference to conventional antipsychotics in patients with chronic schizophrenia has been supported by several modelled studies, including a cost-effectiveness analysis that compared risperidone and haloperidol in chronic schizophrenia and a cost-utility study that compared the drug with oral haloperidol, depot haloperidol decanoate and depot fluphenazine decanoate for 1 year's treatment of an initially hospitalised chronic schizophrenic patient with moderate symptoms. |
1998-09-22 |
2023-08-12 |
Not clear |
| R H Foster, K L Go. Risperidone. A pharmacoeconomic review of its use in schizophrenia. PharmacoEconomics. vol 14. issue 1. 1998-09-22. PMID:10182198. |
risperidone had favourable cost-benefit ratios relative to conventional antipsychotic treatment in a study that investigated a scenario in which all patients hospitalised with newly diagnosed schizophrenia received conventional antipsychotic therapy for 6 months, and then those who did not respond received a 6-month trial of risperidone or clozapine. |
1998-09-22 |
2023-08-12 |
Not clear |
| R H Foster, K L Go. Risperidone. A pharmacoeconomic review of its use in schizophrenia. PharmacoEconomics. vol 14. issue 1. 1998-09-22. PMID:10182198. |
the other compared risperidone, olanzapine and oral haloperidol for the treatment of schizophrenia. |
1998-09-22 |
2023-08-12 |
Not clear |
| G Remington, S Kapur, R Zipursk. APA Practice Guideline for schizophrenia: risperidone equivalents. American Psychiatric Association. The American journal of psychiatry. vol 155. issue 9. 1998-09-16. PMID:9734565. |
apa practice guideline for schizophrenia: risperidone equivalents. |
1998-09-16 |
2023-08-12 |
Not clear |
| L J Cohe. Looking beyond the formulary budget in cost-benefit analysis. The American journal of managed care. vol 3 Suppl. 1998-07-22. PMID:10180337. |
in one study of the newer antipsychotic agent risperidone, the overall annual costs of treating a patient with schizophrenia were reduced by nearly $8,000 (canadian dollars), even though medication costs increased by approximately $1,200 (canadian dollars). |
1998-07-22 |
2023-08-12 |
Not clear |
| M Gutiérrez, J Gibert, J Bobes, M L Herráiz, A Fernánde. [Risperidone in the treatment of acute exacerbation of schizophrenia symptoms]. Actas luso-espanolas de neurologia, psiquiatria y ciencias afines. vol 26. issue 2. 1998-07-20. PMID:9595821. |
[risperidone in the treatment of acute exacerbation of schizophrenia symptoms]. |
1998-07-20 |
2023-08-12 |
Not clear |
| E A Ashleigh, P D Larse. A syndrome of increased affect in response to risperidone among patients with schizophrenia. Psychiatric services (Washington, D.C.). vol 49. issue 4. 1998-07-17. PMID:9550246. |
a syndrome of increased affect in response to risperidone among patients with schizophrenia. |
1998-07-17 |
2023-08-12 |
Not clear |
| E A Ashleigh, P D Larse. A syndrome of increased affect in response to risperidone among patients with schizophrenia. Psychiatric services (Washington, D.C.). vol 49. issue 4. 1998-07-17. PMID:9550246. |
six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia. |
1998-07-17 |
2023-08-12 |
Not clear |
| E A Ashleigh, P D Larse. A syndrome of increased affect in response to risperidone among patients with schizophrenia. Psychiatric services (Washington, D.C.). vol 49. issue 4. 1998-07-17. PMID:9550246. |
the authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase. |
1998-07-17 |
2023-08-12 |
Not clear |
| W Werapongset, S Chaisirikul, W Chrujiporn, T Visanuyothin, D Kessawai, C Charisilp, N Ratanachata, K Sanichwannakul, P Wangdee, A Bunditchate, P Ukranan. Efficacy and tolerability of risperidone in chronic schizophrenic Thai patients. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. vol 81. issue 5. 1998-07-09. PMID:9623031. |
risperidone is a novel serotonin-dopamine antagonist antipsychotic in a class of benzisoxazole derivative which has been shown to be effective in reducing psychotic symptoms in schizophrenia. |
1998-07-09 |
2023-08-12 |
Not clear |
| N P Nai. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group. Journal of clinical psychopharmacology. vol 18. issue 2. 1998-06-12. PMID:9555595. |
therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. |
1998-06-12 |
2023-08-12 |
Not clear |
| N P Nai. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group. Journal of clinical psychopharmacology. vol 18. issue 2. 1998-06-12. PMID:9555595. |
risperidone given once daily at 8 mg is as effective as twice-daily administration of 4 mg in the treatment of acute exacerbations of schizophrenia. |
1998-06-12 |
2023-08-12 |
Not clear |